14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
BDX vs PMI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Becton, Dickinson and Co. (BDX) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BDX carries a Unified Composite Score of 47.9/100 (HOLD) at $212.68 (16.0x Forward P/E, 15.7% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin).
Growth vs. Quality Trade-Off: BDX earns the overall head-to-head edge with a stronger Unified Composite Score (47.9/100 HOLD vs. PMI 48.4/100 HOLD) and 0.16β · 26% Vol risk profile, whereas PMI leads top-line expansion (+38.6% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BDX vs PMI Key Questions & Quantitative Answers
As of Nov 19, 2026, Becton, Dickinson and Co. (BDX) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BDX carries a Unified Composite Score of 47.9/100 (HOLD) at $212.68 (16.0x Forward P/E, 15.7% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin). Growth vs. Quality Trade-Off: BDX earns the overall head-to-head edge with a stronger Unified Composite Score (47.9/100 HOLD vs. PMI 48.4/100 HOLD) and 0.16β · 26% Vol risk profile, whereas PMI leads top-line expansion (+38.6% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
BDX leads the Growth & Scale pillar: BDX posts -10.5% YoY revenue growth and +47.6% YoY earnings growth on $19.5B TTM revenue (47.0% gross margin, 15.7% operating margin), compared with PMI at +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BDX cumulative revenue shifted +36.7% while PMI shifted N/A. In operating R&D and SG&A reinvestment, BDX deploys 31.3% of Rev ($6.09B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PMI.
BDX screens cheaper on headline valuation multiples. BDX trades at 16.0x Forward P/E, 42.7x Trailing P/E, 0.99x PEG, and 4.2x EV/Revenue (19.1% FCF margin), whereas PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BDX (5.7% ROE) versus PMI (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, BDX carries 28.4% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.41x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (0.16β · 26% Vol realized risk). By comparison, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.